Bristol-Myers Squibb Company

BMY

US1101221083

Pharmaceuticals

Market Closed - NYSE Other stock markets 04:00:02 2026-06-29 pm EDT			After hours 08:00:00 pm
58.56 ^USD	+1.81%		56.61	-3.33%

Jun. 29	Bristol Myers' CELMoD Franchise Remains Underappreciated Ahead of Iberdomide Decision, RBC Says	MT
Jun. 29	Bristol-Myers Squibb Company(NYSE:BMY) dropped from Russell Top 200 Growth Benchmark	CI

Bristol Myers Squibb Logs Higher 1Q Sales Driven by Growth Portfolio

Published on 04/30/2026 at 07:16 am EDT

Dow Jones

BRISTOL-MYERS SQUIBB COMPANY

+1.81%

By Katherine Hamilton

Bristol Myers Squibb posted higher first-quarter revenue boosted by its portfolio of newer treatments for heart and blood conditions.

The biopharmaceutical company on Thursday posted a profit of $2.68 billion, or $1.31 a share, compared with $2.46 billion, or $1.20 a share, a year earlier.

Stripping out certain one-time items, adjusted per-share earnings were $1.58, ahead of the $1.42 anticipated by analysts, according to FactSet.

Revenue rose 3% to $11.49 billion. Analysts surveyed by FactSet forecast revenue of $10.93 billion.

Sales in Bristol Myers Squibb's growth portfolio rose 12%, driven by Camzyos, Breyanzi and Reblozyl. The drugs are designed to treat heart disease, lymphoma and blood disorders, respectively.

Revenue in its legacy portfolio decreased 6% due to challenges from generic brands. Its legacy brand Eliquis, a blood thinner, saw higher demand and sales.

International sales rose 11% to $3.7 billion, while U.S. sales declined 1% to $7.8 billion.

The company reaffirmed its full-year guidance and said revenue and earnings are trending toward the upper end of the ranges it previously shared.

Write to Katherine Hamilton at katherine.hamilton@wsj.com

(END) Dow Jones Newswires

04-30-26 0714ET

Latest news about Bristol-Myers Squibb Company

Jun. 29	Bristol Myers' CELMoD Franchise Remains Underappreciated Ahead of Iberdomide Decision, RBC Says	MT
Jun. 29	Bristol-Myers Squibb Company(NYSE:BMY) dropped from Russell Top 200 Growth Benchmark	CI
Jun. 29	Bristol-Myers Squibb Company(NYSE:BMY) dropped from Russell 3000E Growth Benchmark	CI
Jun. 28	Bristol-Myers Squibb Company(NYSE:BMY) dropped from Russell 3000 Growth Benchmark	CI
Jun. 28	Bristol-Myers Squibb Company(NYSE:BMY) dropped from Russell 1000 Growth Benchmark	CI
Jun. 25	Major deals involving US drugmakers and biotechs over the past decade	RE
Jun. 23	GSK executives, including non-exec chair, buy shares	AN
Jun. 17	Bristol Myers Squibb Declares Quarterly Dividend, Payable on August 3, 2026	CI
Jun. 17	Bristol-Myers Squibb Keeps Quarterly Dividend at $0.63 per Share, Payable August 3 to shareholders of Record July 2	MT
Jun. 15	China's Harbour BioMed to focus on another patent case after $20 million damages award	RE
Jun. 11	Takeda's AI-crafted psoriasis pill tops Bristol Myers' Sotyktu in head-to-head trial	RE
Jun. 09	Bristol-Myers Squibb Company Presents at Goldman Sachs 47th Annual Global Healthcare Conference 2026, Jun-09-2026 02:00 PM
Jun. 03	Arcus Biosciences Partners With Bristol Myers Squibb to Develop Kidney Cancer Treatment	MT
Jun. 03	Arcus to Supply Experimental Kidney Cancer Drug for Myers Squibb Trial	DJ
Jun. 03	Arcus Biosciences, Inc. and Bristol Myers Squibb Enter Clinical Trial Collaboration and Supply Agreement to Evaluate Casdatifan in Combination with PD-L1/VEGF-A Bispecific Immunomodulator to Treat Kidney Cancer	CI

Chart Bristol-Myers Squibb Company

Duration

Period

BMY: Dynamic Chart

Bristol-Myers Squibb Company est spécialisé dans le développement, la fabrication et la commercialisation de produits pharmaceutiques. Les produits sont destinés au traitement des cancers, des maladies cardio-vasculaires, de l'hépatite, des maladies immunitaires et des désordres psychiatriques. The United States account for 69.1% of net sales.

Employees

32,500

Sector

Pharmaceuticals

Calendar

Jul. 02 - Ex-dividend date - 0.63 USD

More about the company